Home › Trial NCT05154994
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
- Trial IDNCT05154994
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorUniversity of Utah
- Enrollment7
- Start date2022-01-14
- ConditionsInfiltrating Urothelial Carcinoma, Sarcomatoid Variant · Locally Advanced Urothelial Carcinoma · Metastatic Urothelial Carcinoma · Unresectable Urothelial Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.